Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference
Alimera Sciences (Nasdaq: ALIM) announced that its President and CEO, Rick Eiswirth, will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:00 pm ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alimera Sciences (Nasdaq: ALIM) announced that its President and CEO, Rick Eiswirth, will present at the Benzinga Biotech Small Cap Conference on March 25, 2021, at 12:00 pm ET. The conference will take place from March 24-25, 2021. Investors can view Eiswirth's presentation after registration and request a 1x1 meeting. Alimera is focused on the development of ophthalmic pharmaceuticals for retinal diseases, addressing a significant need in an aging population. For more information, visit www.alimerasciences.com.
Details
News Market Reaction – ALIM
The recorded move for ALIM in the trading session of this news was -1.10%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ATLANTA, March 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announced today that President and CEO Rick Eiswirth will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021.
Mr. Eiswirth will present on March 25 at 12:00 pm ET.
Investors can view Mr. Eiswirth’s general corporate presentation once they register for the conference here and can also request a 1x1 meeting with Mr. Eiswirth.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com | For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.